文献速递肾癌与肾肿瘤

高危非转移性肾细胞癌的腹膜后淋巴结清扫:ASSURE(ECOG-ACRIN 2805)辅助治疗试验分析

Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.
PubMed 文献 · J Urol · 2017-07-18

该研究基于ASSURE试验中完全切除的高危非转移性肾细胞癌患者,比较行与未行淋巴结清扫者的生存结局。淋巴结清扫组与未清扫组的总体生存无显著获益(HR 1.14,95%CI 0.93-1.39,p=0.20),且未增加手术并发症风险(14.2% vs 13.4%,p=0.63)。作者认为淋巴结清扫在高危肾细胞癌中的获益仍不确定。

要点

  • ASSURE试验中1943例患者有701例(36.1%)行淋巴结清扫,其中cN0患者占30.1%。
  • 淋巴结清扫组中位切除3枚淋巴结(IQR 1-8),pN+率为23.4%。
  • 淋巴结清扫相对未清扫无总体生存获益(HR 1.14,95%CI 0.93-1.39,p=0.20)。

核心结论

  • 在高危肾细胞癌手术患者中,淋巴结清扫的获益仍不确定。
  • 未来应开展将高危肾细胞癌患者随机分配至特定淋巴结清扫模板的前瞻性试验。

研究设计与样本

  • ASSURE(ECOG-ACRIN 2805)辅助治疗试验的回顾性分析,患者为完全切除的高危非转移性肾细胞癌,随机接受辅助索拉非尼、舒尼替尼或安慰剂。
  • 淋巴结清扫用于cN+疾病或由外科医生决定,行清扫者与未行清扫者进行比较。
  • 主要结局为淋巴结清扫相关的总体生存,次要结局为无病生存、与行淋巴结清扫相关的因素及手术并发症。

主要发现

  • 1943例患者中701例(36.1%)行淋巴结清扫,包括所有可切除的cN+患者及30.1%的cN0患者。
  • 淋巴结清扫组中位切除3枚淋巴结(IQR 1-8),pN+率为23.4%。
  • 淋巴结清扫相对未清扫无总体生存获益(HR 1.14,95%CI 0.93-1.39,p=0.20)。
  • 在行淋巴结清扫的pN+患者中,辅助治疗相对安慰剂未观察到总体生存或无病生存改善。
  • 淋巴结清扫未增加手术并发症风险(14.2% vs 13.4%,p=0.63)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Lymphadenectomy is a well established practice for many urological malignancies but its role in renal cell carcinoma is less clear. Our primary objective was to determine whether lymphadenectomy impacted survival in patients with fully resected, high risk renal cell carcinoma. MATERIALS AND METHODS: Patients with fully resected, high risk, nonmetastatic renal cell carcinoma were randomized to adjuvant sorafenib, sunitinib or placebo in the ASSURE (Adjuvant Sorafenib and Sunitinib for Unfavorable Renal Carcinoma) trial. Lymphadenectomy was performed for cN+ disease or at surgeon discretion. Patients treated with lymphadenectomy were compared to patients in the trial who did not undergo lymphadenectomy. The primary outcome was overall survival associated with lymphadenectomy. Secondary outcomes were disease free survival, factors associated with performing lymphadenectomy and surgical complications. RESULTS: Of the 1,943 patients in ASSURE 701 (36.1%) underwent lymphadenectomy, including all resectable patients with cN+ and 30.1% of those with cN0 disease. A median of 3 lymph nodes (IQR 1-8) were removed and the rate of pN+ disease in the lymphadenectomy group was 23.4%. There was no overall survival benefit for lymphadenectomy relative to no lymphadenectomy (HR 1.14, 95% CI 0.93-1.39, p = 0.20). In patients with pN+ disease who underwent lymphadenectomy no improvement in overall or disease-free survival was observed for adjuvant therapy relative to placebo. Lymphadenectomy did not confer an increased risk of surgical complications (14.2% vs 13.4%, p = 0.63). CONCLUSIONS: The benefit of lymphadenectomy in patients undergoing surgery for high risk renal cell carcinoma remains uncertain. Future strategies to answer this question should include a prospective trial in which patients with high risk renal cell carcinoma are randomized to specific lymphadenectomy templates.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Ristau BT, Manola J, Haas NB, et al. Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial. J Urol. 2017. PMID: 28728992. doi:10.1016/j.juro.2017.07.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。